Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis.

Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis.

The GPR17 receptor, expressed on oligodendroglial precursors (OPCs, the myelin producing cells), has emerged as an attractive target for a pro-myelinating strategy in multiple sclerosis (MS). However, the proof-of-concept that selective GPR17 ligands actually exert protective activity in vivo is sti...

Full description

Bibliographic Details
Main Authors: Chiara Parravicini, Davide Lecca, Davide Marangon, Giusy Tindara Coppolino, Simona Daniele, Elisabetta Bonfanti, Marta Fumagalli, Luca Raveglia, Claudia Martini, Elisabetta Gianazza, Maria Letizia Trincavelli, Maria P Abbracchio, Ivano Eberini
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0231483

Internet

https://doi.org/10.1371/journal.pone.0231483

Similar Items